Is your dog scheduled for hip surgery? Participate in our landmark study investigating the long-term joint health of dogs treated with Librela™. By analyzing tissue typically discarded during surgery, we aim to identify which patients are the best candidates for anti-NGF therapy—helping veterinarians provide safer, more personalized care for every dog.

CANDO has officially launched its first study, investigating the long-term effects of anti-NGF therapies like Librela™ on joint health. By analyzing histological data from naturally occurring osteoarthritis, we aim to establish new safety benchmarks that ensure the best outcomes for every dog.

From vision to reality: CANDO’s inaugural strategic meeting in January finalized the governance and research roadmap necessary to transform veterinary arthritis care. With our infrastructure now in place, we are ready to launch high-impact clinical trials that bridge the gap between the lab and the living room.